Drug intelligence / Profile preview

anti-parvovirus IgY

Development stage: Preclinical
Lead developer: Immunology Research Institute in Gifu
Modality: Antibody-Based Therapeutics
Administration: Oral

Overview

Anti-parvovirus IgY is an egg yolk-derived immunoglobulin (IgY) developed by the Immunology Research Institute in Gifu for the treatment and prevention of canine parvovirus (CPV) infection. Produced by immunizing hens with CPV antigens, the resulting IgY antibodies are harvested from egg yolks. These antibodies provide passive immunity by binding to and neutralizing the virus in the gastrointestinal tract, thereby preventing viral entry into host cells and reducing the severity of clinical symptoms. This approach is particularly useful in veterinary medicine as a cost-effective alternative to mammalian-derived antibodies.

Other names: anti-CPV IgYegg yolk immunoglobulin against canine parvovirus

Targets

CPV capsid (Canine parvovirus capsid protein)

Beyond the preview

Go deeper on anti-parvovirus IgY.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-parvovirus IgY.

Explore the full profile